• The initiative’s partner Université de Montpellier - Institut des Biomolécules Max Mousseron (IBMM) was in charge of the presentation of the therapy model of the project
• The event was held between the 19th and the 22nd of October in the French Alps

The latest innovations and technologies of CARDIOPATCH Project, a European R+D initiative aimed to boost the quality of life of myocardial infarction patients, were showcased last October at Biomat congress, a scientific event held in France to review the new trends on the development of biomaterials.

The CARDIOPATCH’s partner Université de Montpellier - Institut des Biomolécules Max Mousseron (IBMM) was in charge of the presentation of the therapy model of the project, based on cellular regenerative medicine and 3D printing technologies. 

Specifically, CARDIOPATCH project, co-funded by the Interreg Sudoe Programme through the European Regional Development Fund (ERDF), will develop a stem-cell smart patch able to regenerate tissues damaged by infarction. The initiative will also create a roll-up 3D device which will allow the patch implantation in the heart through less invasive methods and a 3D system to generalize the patch production and streamline transport.

The Biomat congress, held between the 19th and the 22nd of October in the French Alps, gathered together researchers, industrialists and clinicians with the aim of exchanging points of view and establishing synergies in the development and evaluation of biomaterials.

Piloted by the French Association for the Development of Biomaterials, the event provided the opportunity of discussing different topics related to tissue regeneration obtained by 3D printed materials. 

The congress was structured on various sessions around European and international research, scaffold design, lab to clinic, data analysis, monitoring, modeling and scaffold architectures and cell fate.

Led by Clínica Universidad de Navarra (CUN), CARDIOPATCH project includes partners from Spain, France and Portugal: CIMA Universidad de Navarra, via the Foundation for Applied Medical Research, Leartiker Technology Center, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, communication agency GUK, Centre Hospitalier Universitaire de Toulouse, the University of Montpellier (UM) - Institut des Biomolécules Max Mousseron (IBMM), GenIbet Biopharmaceuticals and the Instituto de Biologia Experimental e Tecnológica.